(Z)-Endoxifen Shows Dual Mechanism Potential in McCune-Albright Syndrome
Event summary
- Atossa Therapeutics presented preclinical data on (Z)-endoxifen at the AACR Special Conference on Rare Cancers on July 18, 2026.
- (Z)-endoxifen demonstrated dual modulation of estrogen receptor and PKC-β/AKT pathways in McCune-Albright Syndrome-associated Peripheral Precocious Puberty (MAS-PPP).
- The study used weighted gene expression signatures and integrated phosphoproteomic/RNA-seq datasets to assess pathway modulation.
- (Z)-endoxifen downregulated cell-cycle progression programs while modulating estrogen-response pathways.
The big picture
Atossa Therapeutics' data highlights a potential therapeutic gap in McCune-Albright Syndrome, where current treatments primarily target estrogen production but may not fully address downstream proliferative signaling. The findings position (Z)-endoxifen as a differentiated candidate with relevance to both rare diseases and oncology, aligning with broader trends in precision medicine and mechanism-driven drug development.
What we're watching
- Clinical Translation
- Whether preclinical findings will translate into clinical efficacy for MAS-PPP and other estrogen-driven conditions.
- Regulatory Strategy
- The pace at which Atossa Therapeutics advances (Z)-endoxifen through regulatory pathways for rare disease indications.
- Market Expansion
- How the dual-mechanism profile of (Z)-endoxifen positions it against existing therapies in oncology and endocrine disorders.